Summary
Niemann–Pick disease type C (NPC) is an autosomal recessive, neurovisceral lipid storage disorder. Mutations in two genes (NPC1 and NPC2) produce indistinguishable clinical phenotypes by biochemical mechanisms that have not yet been entirely clarified. The wide spectrum of clinical presentations of NPC includes hepatic and pulmonary disease as well as a range of neuropsychiatric disorders. Late-onset disease has been increasingly recognized as the biochemical diagnosis of NPC has been more widely applied in adult neurology clinics. The clinical presentation and follow-up of 94 patients with NPC is described, 58 of whom were still alive at the time this report was prepared. The age at diagnosis ranged from the prenatal period (with hydrops fetalis) up to 51 years. This review of NPC patients in the UK confirms the phenotypic variability of this inherited lipid storage disorder reported elsewhere. Although a non-neuronopathic variant has been described, most patients in this series who survived childhood inevitably suffered neurological and in some cases neuropsychiatric deterioration. While symptomatic treatment, such as anticholinergic and antiepileptic drugs, can alleviate some aspects of the disease, there is a clear need to develop a specific treatment for this progressively debilitating neurodegenerative disorder.
Similar content being viewed by others
Abbreviations
- NPC:
-
Niemann–Pick disease type C
References
Butler JD, Blanchette-Mackie J, Goldin E, etal (1992) Progesterone blocks cholesterol translocation from lysosomes. J Biol Chem 267: 2797–2805.
Carstea ED, Morris JA, Coleman KG, etal (1997) Niemann–Pick disease: homology to mediators of cholesterol homeostasis. Science 277: 228–231.
Cox TM, Aerts JM, Andria G, etal (2003) The role of iminosugar N-butydeoxynojimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26: 513–526.
Elstein D, Hollac C, Aerts JM, etal (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyledeoxynojrimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27: 757–766.
Erickson RP, Garver WS, Camargo F, Hossain GS, Heindenreich RA (2000) Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann–Pick C mice. J Inherit Metab Dis 23: 54–62.
Grau AJ, Weisbrod M, Niethammer R, etal (1997) Niemann-Pick disease Type C mimicking features of multiple sclerosis. J Neurol/Neurosurg Psych 63: 552.
Griffin LD, Gong W, Verot L, Mellon SH (2004) Niemann–Pick type C involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 10: 704–711.
Hsu YS, Hwu WL, Huang SF, etal (1999) Niemann–Pick C disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant 24: 103–107.
Imrie J, Vijayaraghaven S, Whitehouse C, etal (2002) Niemann–Pick disease type C in adults. J Inherit Metab Dis 25: 491–500.
Kaminski WE, Kluemann, HH, Ibach B etal (2002) Identification of novel mutations in the NPC 1 gene in German patients with Niemann-Pick disease. J Inherit Metab Dis 25: 385–389.
Kelly DA, Portmann B, Mowat AP, etal (1994) Niemann–Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr 124: 665–666.
Lachmann RH, te Vruchte D, Lloyd-Evans D, etal (2004) Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C. Neurobiol Dis 16: 654–658.
Mieli-Vergani G, Howard ER, Mowat AP (1991) Liver disease in infancy: a 20 year perspective. Gut Suppl S121–128.
Millat G, Marcais C, Rafi MA, etal (1999) Niemann–Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. Am J Hum Genet 65: 1321–1329.
Patterson MC, Di Bisceglie AM, Higgins, etal (1993) The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann–Pick disease type C. Neurology 43: 61–64.
Patterson MC, Vanier MT, Suzuki K, etal (2001) Niemann–Pick disease type C: a lipid trafficking disorder. In: Scriver CR, Beaudetal Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3611–3633.
Patterson M, Vecchio D, Prady H, Ait-Aussa N, Abel L, Wraith E (2005) Oral miglustat in adult and pediatric patients with Niemann–Pick type C (NPC) disease: rationale, methodology and interim analyses of a clinical study. American Society for Human Genetics, Salt Lake City, October 2005 [Poster].
Pentchev PG, Comly ME, Kruth HS, etal (1985) A defect in cholesterol esterification in Niemann–Pick disease (type C) patients. Proc Natl Acad Sci USA 82: 8247–8251.
Steinberg SJ, Ward CP, Fensom AH (1994) Complementation studies in Niemann–Pick disease type C indicate the existence of a second group. Med Genet 31: 317–320.
Trendleburg G, Vanier MT, Maza S, etal (2006) Niemann–Pick type C disease in a 68-year-old patient. J Neurol Neurosurg Psychiatry 77: 997–998.
Vanier MT, Millat G (2003) Niemann–Pick disease type C. Clin Genet 64: 269–281.
Vanier MT, Millat G (2004) Structure and function of the NPC2 protein. Biochim Biophys Acta 1685: 14–21.
Vanier MT, Rodriguez-Lafrasse C, Rousson R, etal (1991) Type C Niemann–Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL-derived cholesterol processing. Biochim Biophys Acta 1096: 1328.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Michael Gibson
Competing interests: None declared
An erratum to this article is available at http://dx.doi.org/10.1007/s10545-007-9986-2.
Rights and permissions
About this article
Cite this article
Imrie, J., Dasgupta, S., Besley, G.T.N. et al. The natural history of Niemann–Pick disease type C in the UK. J Inherit Metab Dis 30, 51–59 (2007). https://doi.org/10.1007/s10545-006-0384-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-006-0384-7